カテゴリー： GlobalInfoResearch, 世界, 医療/バイオ

世界のリツキサン（リツキシマブ）&バイオシミラー市場2023年：企業・地域・タイプ・用途別分析

◆英語タイトル：Global Rituxan (Rituximab) and Biosimilar Market 2023 by Manufacturers, Regions, Type and Application, Forecast to 2029

GlobalInfoResearchが発行した調査報告書（GIR23SM8032）◆商品コード：GIR23SM8032
◆発行会社（リサーチ会社）：GlobalInfoResearch
◆発行日：2023年9月
◆ページ数：71
◆レポート形式：英語 / PDF
◆納品方法：Eメール（注文後2-3日）
◆調査対象地域：グローバル
◆産業分野：医薬品＆ヘルスケア
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD3,480 ⇒換算￥528,960見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）USD5,220 ⇒換算￥793,440見積依頼/購入/質問フォーム
Corporate User（同一法人内共有可）USD6,960 ⇒換算￥1,057,920見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

GlobalInfoResearchの最新の調査によると、世界のリツキサン（リツキシマブ）&バイオシミラーの市場規模は2022年のxxx米ドルから2029年にはxxx米ドルと推定され、xxx％の成長率で成長すると予想されます。新型コロナウイルス感染症とロシア・ウクライナ戦争の影響を考慮しながら市場規模を推計しました。
このレポートは、世界のリツキサン（リツキシマブ）&バイオシミラー市場に関する詳細かつ包括的な分析の結果です。定量的分析と定性的分析データが、メーカー別、地域別、国別、タイプ別、用途別に記載されています。

市場は常に変化しているため、本レポートでは、競争、需要と供給の傾向、および多くの市場にわたる需要の変化に影響する主要な要因を調査しました。主要な競合他社の企業概要と製品例、および2023年の市場シェア予測も記載しました。

本レポートの主な目的は次のとおりです。
- 世界および主要国の市場機会の規模を決定するため
- リツキサン（リツキシマブ）&バイオシミラーの成長可能性を評価するため
- 各製品および最終用途市場の将来の成長を予測するため
- 市場に影響を与える競争要因を評価するため

リツキサン（リツキシマブ）&バイオシミラー市場はタイプと用途によって区分されます。2018年～2029年において、量と金額の観点からタイプ別および用途別セグメントの売上予測データを提供します。この分析は、適格なニッチ市場をターゲットにすることでビジネスを拡大するのに役立ちます。

タイプ別セグメント
・ブランド、バイオシミラー

用途別セグメント
・子供、大人

主要な市場プレーヤー
・Roche、Teva、Pfizer、Amgen

地域別セグメントは次の地域・国をカバーします。
・北米（米国、カナダ、メキシコ）
・ヨーロッパ（ドイツ、フランス、イギリス、ロシア、イタリア）
・アジア太平洋（日本、中国、韓国、インド、東南アジア、オーストラリア）
・南アメリカ（ブラジル、アルゼンチン、コロンビア）
・中東およびアフリカ（サウジアラビア、UAE、エジプト、南アフリカ）

本調査レポートの内容は計15章あります。
・第1章では、リツキサン（リツキシマブ）&バイオシミラー製品の調査範囲、市場の概要、市場の成長要因・阻害要因、および市場動向について説明します。
・第2章では、主要なリツキサン（リツキシマブ）&バイオシミラーメーカーの企業概要、2019年～2022年までのリツキサン（リツキシマブ）&バイオシミラーの価格、販売量、売上、市場シェアを掲載しています。
・第3章では、主要なリツキサン（リツキシマブ）&バイオシミラーメーカーの競争状況、販売量、売上、世界市場シェアが重点的に比較分析されています。
・第4章では、2018年～2029年までの地域別リツキサン（リツキシマブ）&バイオシミラーの販売量、売上、成長性を示しています。
・第5、6章では、2018年～2029年までのリツキサン（リツキシマブ）&バイオシミラーのタイプ別と用途別の市場規模、市場シェアと成長率を掲載しています。
・第7、8、9、10、11章では、2018年～2022年までの世界の主要国での販売量、売上、市場シェア、並びに2023年～2029年までの主要地域でのリツキサン（リツキシマブ）&バイオシミラー市場予測を収録しています。
・第12章では、市場力学、成長要因、阻害要因、トレンド、ポーターズファイブフォース分析、新型コロナウイルス感染症とロシア・ウクライナ戦争の影響を掲載しています。
・第13章では、主要な原材料、主要なサプライヤー、およびリツキサン（リツキシマブ）&バイオシミラーの産業チェーンを掲載しています。
・第14、15章では、リツキサン（リツキシマブ）&バイオシミラーの販売チャネル、販売業者、顧客、調査結果について説明します。

・市場概要
– リツキサン（リツキシマブ）&バイオシミラーの概要
– タイプ別分析（2018年vs2022年vs2029年）：ブランド、バイオシミラー
– 用途別分析（2018年vs2022年vs2029年）：子供、大人
– 世界のリツキサン（リツキシマブ）&バイオシミラー市場規模・予測
– 世界のリツキサン（リツキシマブ）&バイオシミラー生産能力分析
– 市場の成長要因・阻害要因・動向
・メーカー情報（企業概要、製品概要、販売量、価格、売上）
– Roche、Teva、Pfizer、Amgen
・メーカー別市場シェア・市場集中度
・地域別市場分析2018年-2029年
・タイプ別分析2018年-2029年：ブランド、バイオシミラー
・用途別分析2018年-2029年：子供、大人
・リツキサン（リツキシマブ）&バイオシミラーの北米市場
– タイプ別市場規模2018年-2029年
– 用途別市場規模2018年-2029年
– 主要国別市場規模：アメリカ、カナダ、メキシコなど
・リツキサン（リツキシマブ）&バイオシミラーのヨーロッパ市場
– タイプ別市場規模2018年-2029年
– 用途別市場規模2018年-2029年
– 主要国別市場規模：ドイツ、イギリス、フランス、ロシア、イタリアなど
・リツキサン（リツキシマブ）&バイオシミラーのアジア市場
– タイプ別市場規模2018年-2029年
– 用途別市場規模2018年-2029年
– 主要国別市場規模：中国、日本、韓国、インド、東南アジア、オーストラリアなど
・リツキサン（リツキシマブ）&バイオシミラーの南米市場
– タイプ別市場規模2018年-2029年
– 用途別市場規模2018年-2029年
– 主要国別市場規模：ブラジル、アルゼンチンなど
・リツキサン（リツキシマブ）&バイオシミラーの中東・アフリカ市場
– タイプ別市場規模2018年-2029年
– 用途別市場規模2018年-2029年
– 主要国別市場規模：サウジアラビア、トルコ、エジプト、南アフリカなど
・市場力学（成長要因、阻害要因、トレンド、ポーターズファイブフォース分析）
・原材料および産業チェーン
・販売チャネル、流通業者・代理店、顧客リスト
・調査の結果・結論

❖ レポートの目次 ❖

1 Market Overview
1.1 Product Overview and Scope of Rituxan (Rituximab) and Biosimilar
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Rituxan (Rituximab) and Biosimilar Consumption Value by Type: 2018 Versus 2022 Versus 2029
1.3.2 Brand
1.3.3 Biosimilar
1.4 Market Analysis by Application
1.4.1 Overview: Global Rituxan (Rituximab) and Biosimilar Consumption Value by Application: 2018 Versus 2022 Versus 2029
1.4.2 Child
1.4.3 Adult
1.5 Global Rituxan (Rituximab) and Biosimilar Market Size & Forecast
1.5.1 Global Rituxan (Rituximab) and Biosimilar Consumption Value (2018 & 2022 & 2029)
1.5.2 Global Rituxan (Rituximab) and Biosimilar Sales Quantity (2018-2029)
1.5.3 Global Rituxan (Rituximab) and Biosimilar Average Price (2018-2029)
2 Manufacturers Profiles
2.1 Roche
2.1.1 Roche Details
2.1.2 Roche Major Business
2.1.3 Roche Rituxan (Rituximab) and Biosimilar Product and Services
2.1.4 Roche Rituxan (Rituximab) and Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 Roche Recent Developments/Updates
2.2 Teva
2.2.1 Teva Details
2.2.2 Teva Major Business
2.2.3 Teva Rituxan (Rituximab) and Biosimilar Product and Services
2.2.4 Teva Rituxan (Rituximab) and Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 Teva Recent Developments/Updates
2.3 Pfizer
2.3.1 Pfizer Details
2.3.2 Pfizer Major Business
2.3.3 Pfizer Rituxan (Rituximab) and Biosimilar Product and Services
2.3.4 Pfizer Rituxan (Rituximab) and Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 Pfizer Recent Developments/Updates
2.4 Amgen
2.4.1 Amgen Details
2.4.2 Amgen Major Business
2.4.3 Amgen Rituxan (Rituximab) and Biosimilar Product and Services
2.4.4 Amgen Rituxan (Rituximab) and Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 Amgen Recent Developments/Updates
3 Competitive Environment: Rituxan (Rituximab) and Biosimilar by Manufacturer
3.1 Global Rituxan (Rituximab) and Biosimilar Sales Quantity by Manufacturer (2018-2023)
3.2 Global Rituxan (Rituximab) and Biosimilar Revenue by Manufacturer (2018-2023)
3.3 Global Rituxan (Rituximab) and Biosimilar Average Price by Manufacturer (2018-2023)
3.4 Market Share Analysis (2022)
3.4.1 Producer Shipments of Rituxan (Rituximab) and Biosimilar by Manufacturer Revenue ($MM) and Market Share (%): 2022
3.4.2 Top 3 Rituxan (Rituximab) and Biosimilar Manufacturer Market Share in 2022
3.4.2 Top 6 Rituxan (Rituximab) and Biosimilar Manufacturer Market Share in 2022
3.5 Rituxan (Rituximab) and Biosimilar Market: Overall Company Footprint Analysis
3.5.1 Rituxan (Rituximab) and Biosimilar Market: Region Footprint
3.5.2 Rituxan (Rituximab) and Biosimilar Market: Company Product Type Footprint
3.5.3 Rituxan (Rituximab) and Biosimilar Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
4.1 Global Rituxan (Rituximab) and Biosimilar Market Size by Region
4.1.1 Global Rituxan (Rituximab) and Biosimilar Sales Quantity by Region (2018-2029)
4.1.2 Global Rituxan (Rituximab) and Biosimilar Consumption Value by Region (2018-2029)
4.1.3 Global Rituxan (Rituximab) and Biosimilar Average Price by Region (2018-2029)
4.2 North America Rituxan (Rituximab) and Biosimilar Consumption Value (2018-2029)
4.3 Europe Rituxan (Rituximab) and Biosimilar Consumption Value (2018-2029)
4.4 Asia-Pacific Rituxan (Rituximab) and Biosimilar Consumption Value (2018-2029)
4.5 South America Rituxan (Rituximab) and Biosimilar Consumption Value (2018-2029)
4.6 Middle East and Africa Rituxan (Rituximab) and Biosimilar Consumption Value (2018-2029)
5 Market Segment by Type
5.1 Global Rituxan (Rituximab) and Biosimilar Sales Quantity by Type (2018-2029)
5.2 Global Rituxan (Rituximab) and Biosimilar Consumption Value by Type (2018-2029)
5.3 Global Rituxan (Rituximab) and Biosimilar Average Price by Type (2018-2029)
6 Market Segment by Application
6.1 Global Rituxan (Rituximab) and Biosimilar Sales Quantity by Application (2018-2029)
6.2 Global Rituxan (Rituximab) and Biosimilar Consumption Value by Application (2018-2029)
6.3 Global Rituxan (Rituximab) and Biosimilar Average Price by Application (2018-2029)
7 North America
7.1 North America Rituxan (Rituximab) and Biosimilar Sales Quantity by Type (2018-2029)
7.2 North America Rituxan (Rituximab) and Biosimilar Sales Quantity by Application (2018-2029)
7.3 North America Rituxan (Rituximab) and Biosimilar Market Size by Country
7.3.1 North America Rituxan (Rituximab) and Biosimilar Sales Quantity by Country (2018-2029)
7.3.2 North America Rituxan (Rituximab) and Biosimilar Consumption Value by Country (2018-2029)
7.3.3 United States Market Size and Forecast (2018-2029)
7.3.4 Canada Market Size and Forecast (2018-2029)
7.3.5 Mexico Market Size and Forecast (2018-2029)
8 Europe
8.1 Europe Rituxan (Rituximab) and Biosimilar Sales Quantity by Type (2018-2029)
8.2 Europe Rituxan (Rituximab) and Biosimilar Sales Quantity by Application (2018-2029)
8.3 Europe Rituxan (Rituximab) and Biosimilar Market Size by Country
8.3.1 Europe Rituxan (Rituximab) and Biosimilar Sales Quantity by Country (2018-2029)
8.3.2 Europe Rituxan (Rituximab) and Biosimilar Consumption Value by Country (2018-2029)
8.3.3 Germany Market Size and Forecast (2018-2029)
8.3.4 France Market Size and Forecast (2018-2029)
8.3.5 United Kingdom Market Size and Forecast (2018-2029)
8.3.6 Russia Market Size and Forecast (2018-2029)
8.3.7 Italy Market Size and Forecast (2018-2029)
9 Asia-Pacific
9.1 Asia-Pacific Rituxan (Rituximab) and Biosimilar Sales Quantity by Type (2018-2029)
9.2 Asia-Pacific Rituxan (Rituximab) and Biosimilar Sales Quantity by Application (2018-2029)
9.3 Asia-Pacific Rituxan (Rituximab) and Biosimilar Market Size by Region
9.3.1 Asia-Pacific Rituxan (Rituximab) and Biosimilar Sales Quantity by Region (2018-2029)
9.3.2 Asia-Pacific Rituxan (Rituximab) and Biosimilar Consumption Value by Region (2018-2029)
9.3.3 China Market Size and Forecast (2018-2029)
9.3.4 Japan Market Size and Forecast (2018-2029)
9.3.5 Korea Market Size and Forecast (2018-2029)
9.3.6 India Market Size and Forecast (2018-2029)
9.3.7 Southeast Asia Market Size and Forecast (2018-2029)
9.3.8 Australia Market Size and Forecast (2018-2029)
10 South America
10.1 South America Rituxan (Rituximab) and Biosimilar Sales Quantity by Type (2018-2029)
10.2 South America Rituxan (Rituximab) and Biosimilar Sales Quantity by Application (2018-2029)
10.3 South America Rituxan (Rituximab) and Biosimilar Market Size by Country
10.3.1 South America Rituxan (Rituximab) and Biosimilar Sales Quantity by Country (2018-2029)
10.3.2 South America Rituxan (Rituximab) and Biosimilar Consumption Value by Country (2018-2029)
10.3.3 Brazil Market Size and Forecast (2018-2029)
10.3.4 Argentina Market Size and Forecast (2018-2029)
11 Middle East & Africa
11.1 Middle East & Africa Rituxan (Rituximab) and Biosimilar Sales Quantity by Type (2018-2029)
11.2 Middle East & Africa Rituxan (Rituximab) and Biosimilar Sales Quantity by Application (2018-2029)
11.3 Middle East & Africa Rituxan (Rituximab) and Biosimilar Market Size by Country
11.3.1 Middle East & Africa Rituxan (Rituximab) and Biosimilar Sales Quantity by Country (2018-2029)
11.3.2 Middle East & Africa Rituxan (Rituximab) and Biosimilar Consumption Value by Country (2018-2029)
11.3.3 Turkey Market Size and Forecast (2018-2029)
11.3.4 Egypt Market Size and Forecast (2018-2029)
11.3.5 Saudi Arabia Market Size and Forecast (2018-2029)
11.3.6 South Africa Market Size and Forecast (2018-2029)
12 Market Dynamics
12.1 Rituxan (Rituximab) and Biosimilar Market Drivers
12.2 Rituxan (Rituximab) and Biosimilar Market Restraints
12.3 Rituxan (Rituximab) and Biosimilar Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
12.5 Influence of COVID-19 and Russia-Ukraine War
12.5.1 Influence of COVID-19
12.5.2 Influence of Russia-Ukraine War
13 Raw Material and Industry Chain
13.1 Raw Material of Rituxan (Rituximab) and Biosimilar and Key Manufacturers
13.2 Manufacturing Costs Percentage of Rituxan (Rituximab) and Biosimilar
13.3 Rituxan (Rituximab) and Biosimilar Production Process
13.4 Rituxan (Rituximab) and Biosimilar Industrial Chain
14 Shipments by Distribution Channel
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Rituxan (Rituximab) and Biosimilar Typical Distributors
14.3 Rituxan (Rituximab) and Biosimilar Typical Customers
15 Research Findings and Conclusion
16 Appendix
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer

List of Tables
Table 1. Global Rituxan (Rituximab) and Biosimilar Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Table 2. Global Rituxan (Rituximab) and Biosimilar Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Table 3. Roche Basic Information, Manufacturing Base and Competitors
Table 4. Roche Major Business
Table 5. Roche Rituxan (Rituximab) and Biosimilar Product and Services
Table 6. Roche Rituxan (Rituximab) and Biosimilar Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 7. Roche Recent Developments/Updates
Table 8. Teva Basic Information, Manufacturing Base and Competitors
Table 9. Teva Major Business
Table 10. Teva Rituxan (Rituximab) and Biosimilar Product and Services
Table 11. Teva Rituxan (Rituximab) and Biosimilar Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 12. Teva Recent Developments/Updates
Table 13. Pfizer Basic Information, Manufacturing Base and Competitors
Table 14. Pfizer Major Business
Table 15. Pfizer Rituxan (Rituximab) and Biosimilar Product and Services
Table 16. Pfizer Rituxan (Rituximab) and Biosimilar Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 17. Pfizer Recent Developments/Updates
Table 18. Amgen Basic Information, Manufacturing Base and Competitors
Table 19. Amgen Major Business
Table 20. Amgen Rituxan (Rituximab) and Biosimilar Product and Services
Table 21. Amgen Rituxan (Rituximab) and Biosimilar Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 22. Amgen Recent Developments/Updates
Table 23. Global Rituxan (Rituximab) and Biosimilar Sales Quantity by Manufacturer (2018-2023) & (K Units)
Table 24. Global Rituxan (Rituximab) and Biosimilar Revenue by Manufacturer (2018-2023) & (USD Million)
Table 25. Global Rituxan (Rituximab) and Biosimilar Average Price by Manufacturer (2018-2023) & (US$/Unit)
Table 26. Market Position of Manufacturers in Rituxan (Rituximab) and Biosimilar, (Tier 1, Tier 2, and Tier 3), Based on Consumption Value in 2022
Table 27. Head Office and Rituxan (Rituximab) and Biosimilar Production Site of Key Manufacturer
Table 28. Rituxan (Rituximab) and Biosimilar Market: Company Product Type Footprint
Table 29. Rituxan (Rituximab) and Biosimilar Market: Company Product Application Footprint
Table 30. Rituxan (Rituximab) and Biosimilar New Market Entrants and Barriers to Market Entry
Table 31. Rituxan (Rituximab) and Biosimilar Mergers, Acquisition, Agreements, and Collaborations
Table 32. Global Rituxan (Rituximab) and Biosimilar Sales Quantity by Region (2018-2023) & (K Units)
Table 33. Global Rituxan (Rituximab) and Biosimilar Sales Quantity by Region (2024-2029) & (K Units)
Table 34. Global Rituxan (Rituximab) and Biosimilar Consumption Value by Region (2018-2023) & (USD Million)
Table 35. Global Rituxan (Rituximab) and Biosimilar Consumption Value by Region (2024-2029) & (USD Million)
Table 36. Global Rituxan (Rituximab) and Biosimilar Average Price by Region (2018-2023) & (US$/Unit)
Table 37. Global Rituxan (Rituximab) and Biosimilar Average Price by Region (2024-2029) & (US$/Unit)
Table 38. Global Rituxan (Rituximab) and Biosimilar Sales Quantity by Type (2018-2023) & (K Units)
Table 39. Global Rituxan (Rituximab) and Biosimilar Sales Quantity by Type (2024-2029) & (K Units)
Table 40. Global Rituxan (Rituximab) and Biosimilar Consumption Value by Type (2018-2023) & (USD Million)
Table 41. Global Rituxan (Rituximab) and Biosimilar Consumption Value by Type (2024-2029) & (USD Million)
Table 42. Global Rituxan (Rituximab) and Biosimilar Average Price by Type (2018-2023) & (US$/Unit)
Table 43. Global Rituxan (Rituximab) and Biosimilar Average Price by Type (2024-2029) & (US$/Unit)
Table 44. Global Rituxan (Rituximab) and Biosimilar Sales Quantity by Application (2018-2023) & (K Units)
Table 45. Global Rituxan (Rituximab) and Biosimilar Sales Quantity by Application (2024-2029) & (K Units)
Table 46. Global Rituxan (Rituximab) and Biosimilar Consumption Value by Application (2018-2023) & (USD Million)
Table 47. Global Rituxan (Rituximab) and Biosimilar Consumption Value by Application (2024-2029) & (USD Million)
Table 48. Global Rituxan (Rituximab) and Biosimilar Average Price by Application (2018-2023) & (US$/Unit)
Table 49. Global Rituxan (Rituximab) and Biosimilar Average Price by Application (2024-2029) & (US$/Unit)
Table 50. North America Rituxan (Rituximab) and Biosimilar Sales Quantity by Type (2018-2023) & (K Units)
Table 51. North America Rituxan (Rituximab) and Biosimilar Sales Quantity by Type (2024-2029) & (K Units)
Table 52. North America Rituxan (Rituximab) and Biosimilar Sales Quantity by Application (2018-2023) & (K Units)
Table 53. North America Rituxan (Rituximab) and Biosimilar Sales Quantity by Application (2024-2029) & (K Units)
Table 54. North America Rituxan (Rituximab) and Biosimilar Sales Quantity by Country (2018-2023) & (K Units)
Table 55. North America Rituxan (Rituximab) and Biosimilar Sales Quantity by Country (2024-2029) & (K Units)
Table 56. North America Rituxan (Rituximab) and Biosimilar Consumption Value by Country (2018-2023) & (USD Million)
Table 57. North America Rituxan (Rituximab) and Biosimilar Consumption Value by Country (2024-2029) & (USD Million)
Table 58. Europe Rituxan (Rituximab) and Biosimilar Sales Quantity by Type (2018-2023) & (K Units)
Table 59. Europe Rituxan (Rituximab) and Biosimilar Sales Quantity by Type (2024-2029) & (K Units)
Table 60. Europe Rituxan (Rituximab) and Biosimilar Sales Quantity by Application (2018-2023) & (K Units)
Table 61. Europe Rituxan (Rituximab) and Biosimilar Sales Quantity by Application (2024-2029) & (K Units)
Table 62. Europe Rituxan (Rituximab) and Biosimilar Sales Quantity by Country (2018-2023) & (K Units)
Table 63. Europe Rituxan (Rituximab) and Biosimilar Sales Quantity by Country (2024-2029) & (K Units)
Table 64. Europe Rituxan (Rituximab) and Biosimilar Consumption Value by Country (2018-2023) & (USD Million)
Table 65. Europe Rituxan (Rituximab) and Biosimilar Consumption Value by Country (2024-2029) & (USD Million)
Table 66. Asia-Pacific Rituxan (Rituximab) and Biosimilar Sales Quantity by Type (2018-2023) & (K Units)
Table 67. Asia-Pacific Rituxan (Rituximab) and Biosimilar Sales Quantity by Type (2024-2029) & (K Units)
Table 68. Asia-Pacific Rituxan (Rituximab) and Biosimilar Sales Quantity by Application (2018-2023) & (K Units)
Table 69. Asia-Pacific Rituxan (Rituximab) and Biosimilar Sales Quantity by Application (2024-2029) & (K Units)
Table 70. Asia-Pacific Rituxan (Rituximab) and Biosimilar Sales Quantity by Region (2018-2023) & (K Units)
Table 71. Asia-Pacific Rituxan (Rituximab) and Biosimilar Sales Quantity by Region (2024-2029) & (K Units)
Table 72. Asia-Pacific Rituxan (Rituximab) and Biosimilar Consumption Value by Region (2018-2023) & (USD Million)
Table 73. Asia-Pacific Rituxan (Rituximab) and Biosimilar Consumption Value by Region (2024-2029) & (USD Million)
Table 74. South America Rituxan (Rituximab) and Biosimilar Sales Quantity by Type (2018-2023) & (K Units)
Table 75. South America Rituxan (Rituximab) and Biosimilar Sales Quantity by Type (2024-2029) & (K Units)
Table 76. South America Rituxan (Rituximab) and Biosimilar Sales Quantity by Application (2018-2023) & (K Units)
Table 77. South America Rituxan (Rituximab) and Biosimilar Sales Quantity by Application (2024-2029) & (K Units)
Table 78. South America Rituxan (Rituximab) and Biosimilar Sales Quantity by Country (2018-2023) & (K Units)
Table 79. South America Rituxan (Rituximab) and Biosimilar Sales Quantity by Country (2024-2029) & (K Units)
Table 80. South America Rituxan (Rituximab) and Biosimilar Consumption Value by Country (2018-2023) & (USD Million)
Table 81. South America Rituxan (Rituximab) and Biosimilar Consumption Value by Country (2024-2029) & (USD Million)
Table 82. Middle East & Africa Rituxan (Rituximab) and Biosimilar Sales Quantity by Type (2018-2023) & (K Units)
Table 83. Middle East & Africa Rituxan (Rituximab) and Biosimilar Sales Quantity by Type (2024-2029) & (K Units)
Table 84. Middle East & Africa Rituxan (Rituximab) and Biosimilar Sales Quantity by Application (2018-2023) & (K Units)
Table 85. Middle East & Africa Rituxan (Rituximab) and Biosimilar Sales Quantity by Application (2024-2029) & (K Units)
Table 86. Middle East & Africa Rituxan (Rituximab) and Biosimilar Sales Quantity by Region (2018-2023) & (K Units)
Table 87. Middle East & Africa Rituxan (Rituximab) and Biosimilar Sales Quantity by Region (2024-2029) & (K Units)
Table 88. Middle East & Africa Rituxan (Rituximab) and Biosimilar Consumption Value by Region (2018-2023) & (USD Million)
Table 89. Middle East & Africa Rituxan (Rituximab) and Biosimilar Consumption Value by Region (2024-2029) & (USD Million)
Table 90. Rituxan (Rituximab) and Biosimilar Raw Material
Table 91. Key Manufacturers of Rituxan (Rituximab) and Biosimilar Raw Materials
Table 92. Rituxan (Rituximab) and Biosimilar Typical Distributors
Table 93. Rituxan (Rituximab) and Biosimilar Typical Customers
List of Figures
Figure 1. Rituxan (Rituximab) and Biosimilar Picture
Figure 2. Global Rituxan (Rituximab) and Biosimilar Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 3. Global Rituxan (Rituximab) and Biosimilar Consumption Value Market Share by Type in 2022
Figure 4. Brand Examples
Figure 5. Biosimilar Examples
Figure 6. Global Rituxan (Rituximab) and Biosimilar Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Figure 7. Global Rituxan (Rituximab) and Biosimilar Consumption Value Market Share by Application in 2022
Figure 8. Child Examples
Figure 9. Adult Examples
Figure 10. Global Rituxan (Rituximab) and Biosimilar Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 11. Global Rituxan (Rituximab) and Biosimilar Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 12. Global Rituxan (Rituximab) and Biosimilar Sales Quantity (2018-2029) & (K Units)
Figure 13. Global Rituxan (Rituximab) and Biosimilar Average Price (2018-2029) & (US$/Unit)
Figure 14. Global Rituxan (Rituximab) and Biosimilar Sales Quantity Market Share by Manufacturer in 2022
Figure 15. Global Rituxan (Rituximab) and Biosimilar Consumption Value Market Share by Manufacturer in 2022
Figure 16. Producer Shipments of Rituxan (Rituximab) and Biosimilar by Manufacturer Sales Quantity ($MM) and Market Share (%): 2021
Figure 17. Top 3 Rituxan (Rituximab) and Biosimilar Manufacturer (Consumption Value) Market Share in 2022
Figure 18. Top 6 Rituxan (Rituximab) and Biosimilar Manufacturer (Consumption Value) Market Share in 2022
Figure 19. Global Rituxan (Rituximab) and Biosimilar Sales Quantity Market Share by Region (2018-2029)
Figure 20. Global Rituxan (Rituximab) and Biosimilar Consumption Value Market Share by Region (2018-2029)
Figure 21. North America Rituxan (Rituximab) and Biosimilar Consumption Value (2018-2029) & (USD Million)
Figure 22. Europe Rituxan (Rituximab) and Biosimilar Consumption Value (2018-2029) & (USD Million)
Figure 23. Asia-Pacific Rituxan (Rituximab) and Biosimilar Consumption Value (2018-2029) & (USD Million)
Figure 24. South America Rituxan (Rituximab) and Biosimilar Consumption Value (2018-2029) & (USD Million)
Figure 25. Middle East & Africa Rituxan (Rituximab) and Biosimilar Consumption Value (2018-2029) & (USD Million)
Figure 26. Global Rituxan (Rituximab) and Biosimilar Sales Quantity Market Share by Type (2018-2029)
Figure 27. Global Rituxan (Rituximab) and Biosimilar Consumption Value Market Share by Type (2018-2029)
Figure 28. Global Rituxan (Rituximab) and Biosimilar Average Price by Type (2018-2029) & (US$/Unit)
Figure 29. Global Rituxan (Rituximab) and Biosimilar Sales Quantity Market Share by Application (2018-2029)
Figure 30. Global Rituxan (Rituximab) and Biosimilar Consumption Value Market Share by Application (2018-2029)
Figure 31. Global Rituxan (Rituximab) and Biosimilar Average Price by Application (2018-2029) & (US$/Unit)
Figure 32. North America Rituxan (Rituximab) and Biosimilar Sales Quantity Market Share by Type (2018-2029)
Figure 33. North America Rituxan (Rituximab) and Biosimilar Sales Quantity Market Share by Application (2018-2029)
Figure 34. North America Rituxan (Rituximab) and Biosimilar Sales Quantity Market Share by Country (2018-2029)
Figure 35. North America Rituxan (Rituximab) and Biosimilar Consumption Value Market Share by Country (2018-2029)
Figure 36. United States Rituxan (Rituximab) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 37. Canada Rituxan (Rituximab) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 38. Mexico Rituxan (Rituximab) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 39. Europe Rituxan (Rituximab) and Biosimilar Sales Quantity Market Share by Type (2018-2029)
Figure 40. Europe Rituxan (Rituximab) and Biosimilar Sales Quantity Market Share by Application (2018-2029)
Figure 41. Europe Rituxan (Rituximab) and Biosimilar Sales Quantity Market Share by Country (2018-2029)
Figure 42. Europe Rituxan (Rituximab) and Biosimilar Consumption Value Market Share by Country (2018-2029)
Figure 43. Germany Rituxan (Rituximab) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 44. France Rituxan (Rituximab) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 45. United Kingdom Rituxan (Rituximab) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 46. Russia Rituxan (Rituximab) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 47. Italy Rituxan (Rituximab) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 48. Asia-Pacific Rituxan (Rituximab) and Biosimilar Sales Quantity Market Share by Type (2018-2029)
Figure 49. Asia-Pacific Rituxan (Rituximab) and Biosimilar Sales Quantity Market Share by Application (2018-2029)
Figure 50. Asia-Pacific Rituxan (Rituximab) and Biosimilar Sales Quantity Market Share by Region (2018-2029)
Figure 51. Asia-Pacific Rituxan (Rituximab) and Biosimilar Consumption Value Market Share by Region (2018-2029)
Figure 52. China Rituxan (Rituximab) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 53. Japan Rituxan (Rituximab) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 54. Korea Rituxan (Rituximab) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 55. India Rituxan (Rituximab) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 56. Southeast Asia Rituxan (Rituximab) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 57. Australia Rituxan (Rituximab) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 58. South America Rituxan (Rituximab) and Biosimilar Sales Quantity Market Share by Type (2018-2029)
Figure 59. South America Rituxan (Rituximab) and Biosimilar Sales Quantity Market Share by Application (2018-2029)
Figure 60. South America Rituxan (Rituximab) and Biosimilar Sales Quantity Market Share by Country (2018-2029)
Figure 61. South America Rituxan (Rituximab) and Biosimilar Consumption Value Market Share by Country (2018-2029)
Figure 62. Brazil Rituxan (Rituximab) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 63. Argentina Rituxan (Rituximab) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 64. Middle East & Africa Rituxan (Rituximab) and Biosimilar Sales Quantity Market Share by Type (2018-2029)
Figure 65. Middle East & Africa Rituxan (Rituximab) and Biosimilar Sales Quantity Market Share by Application (2018-2029)
Figure 66. Middle East & Africa Rituxan (Rituximab) and Biosimilar Sales Quantity Market Share by Region (2018-2029)
Figure 67. Middle East & Africa Rituxan (Rituximab) and Biosimilar Consumption Value Market Share by Region (2018-2029)
Figure 68. Turkey Rituxan (Rituximab) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 69. Egypt Rituxan (Rituximab) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 70. Saudi Arabia Rituxan (Rituximab) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 71. South Africa Rituxan (Rituximab) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 72. Rituxan (Rituximab) and Biosimilar Market Drivers
Figure 73. Rituxan (Rituximab) and Biosimilar Market Restraints
Figure 74. Rituxan (Rituximab) and Biosimilar Market Trends
Figure 75. Porters Five Forces Analysis
Figure 76. Manufacturing Cost Structure Analysis of Rituxan (Rituximab) and Biosimilar in 2022
Figure 77. Manufacturing Process Analysis of Rituxan (Rituximab) and Biosimilar
Figure 78. Rituxan (Rituximab) and Biosimilar Industrial Chain
Figure 79. Sales Quantity Channel: Direct to End-User vs Distributors
Figure 80. Direct Channel Pros & Cons
Figure 81. Indirect Channel Pros & Cons
Figure 82. Methodology
Figure 83. Research Process and Data Source


❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer
★リサーチレポート[ 世界のリツキサン（リツキシマブ）&バイオシミラー市場2023年：企業・地域・タイプ・用途別分析(Global Rituxan (Rituximab) and Biosimilar Market 2023 by Manufacturers, Regions, Type and Application, Forecast to 2029)]についてメールでお問い合わせはこちらでお願いします。
◆関連リサーチレポート◆
  • 世界のエポジェン&バイオシミラー市場2023年：企業・地域・タイプ・用途別分析
  • 世界のルセンティス（ラニビズマブ）&バイオシミラー市場2023年：企業・地域・タイプ・用途別分析
  • 世界のニューラスタ（ペグフィルグラスチム）&バイオシミラー市場2023年：企業・地域・タイプ・用途別分析
  • バイオシミラーモノクローナル抗体のグローバル市場（2023-2032）：アダリムマブ、ベバシズマブ、インフリキシマブ、リツキシマブ、トラスツズマブ、その他

    • ◆H&Iグローバルリサーチのお客様（例）◆